AI-Powered
Pharmaceutical Intelligence
Access to drugs, clinical trials, patents, literatures and news in one search
Try:
AL-102 (Ayala)Crohn DiseasePneumococcal InfectionsFGFRL1APOC3Pfizer Inc.
107
K
Drugs & Biologics
46
K
Targets
1
M
Organizations
983
K
/
256
K
Clinical Trials / Results
69
M
Literatures
17
M
Patents
Recent blog posts
View all blog posts →
Johnson & Johnson’s $14.6 Billion Acquisition of Intra-Cellular Therapies: Caplyta® as a Game-Changer in Mental Health Treatment
Hot Spotlight
9 min read
Johnson & Johnson’s $14.6 Billion Acquisition of Intra-Cellular Therapies: Caplyta® as a Game-Changer in Mental Health Treatment
22 January 2025
Johnson & Johnson announced its acquisition of Intra-Cellular Therapies, a biopharmaceutical company focused on central nervous system (CNS) disorders.
Read →
2024 Global New Drug Approvals: A Comprehensive Review of Breakthrough Therapies and Innovations
Hot Spotlight
9 min read
2024 Global New Drug Approvals: A Comprehensive Review of Breakthrough Therapies and Innovations
16 January 2025
In 2024, the range of diseases treated by globally approved new drugs was diverse, with cancer and rare diseases leading in the total number of new drug approvals.
Read →
Combating Obesity with GLP-1RAs: From Semaglutide to Small-Molecule Agonists and the Role of Patent Analytics in Drug Development
Hot Spotlight
8 min read
Combating Obesity with GLP-1RAs: From Semaglutide to Small-Molecule Agonists and the Role of Patent Analytics in Drug Development
14 January 2025
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered significant attention for their dual effects in glucose control and weight reduction.
Read →
Check out our latest report
View all reports →
Global Drug R&D Express (December 2024)

Global Drug R&D Express (December 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December totaling 131 drugs. Among them, 1 first-to-market drugs and 1 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →
Global Drug R&D Express (Nov 2024)

Global Drug R&D Express (Nov 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of November totaling 132 drugs. Among them, 1 first-to-market drugs and 1 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →
Global Drug R&D Express (October 2024)

Global Drug R&D Express (October 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of October totaling 132 drugs. Among them, 1 first-to-market drugs and 1 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →
Latest news
View all news →
news cover
Vyluma Announces Acceptance of Drug Application for NVK002 by China’s National Medical Products Administration (NMPA)
01 Feb 2025
news cover
Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence
01 Feb 2025
news cover
Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea
01 Feb 2025
news cover
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
01 Feb 2025
Who We Serve
View our solutions →
01
R&D Decision Makers
R&D Decision Makers
We provide R&D decision makers with access to accurate, connected data so they can quickly understand newly-emerged technology trends, have an insight into the competitive landscapes, uncover partnership opportunities, and decide the direction of innovation.
02
Business Development Professionals
Business Development Professionals
We provide 320,000+ life science organizations with drug pipeline and investment history, which help you make informed decisions on potential partnerships or acquisition targets.
03
Pharmaceutical Analyst
Pharmaceutical Analyst
We accelerate the research process for Pharmaceutical Analysts through various connected data, including drug approval, clinical trials, patent, non-patent literature and news. Synapse provides users with a 360-degree view of the competitive and technology landscape!
LifeScience Product Suite
Synapse
Looking for drug development opportunities
Evaluate the value of license-in projects
Screen investment targets
Optimize product pipeline
Current product
Bio
Chase new frontiers in bio-innovation
Stay on top of competitor movements
Validate novelty and freedom to operate searches with ease
Identify sequences for therapeutic activities
View details
Chemical
Explore promising compounds and their applications
Accelerate novelty and freedom to operate reviews
Strengthen competitor analysis
View details
Get started for free today!
Access to drugs, clinical trials, patents, literatures and news in one search.